These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 37924341)
21. [Correlation of 3'-deoxy-3'-18F-fluorothymidine uptake to cell proliferation in lung carcinoma xenografts]. Liu X; Zhou NK; Zhang JM; Liang ZY; Zheng X Ai Zheng; 2006 Dec; 25(12):1512-6. PubMed ID: 17166377 [TBL] [Abstract][Full Text] [Related]
22. Elevated tumor-to-liver uptake ratio (TLR) from Huang J; Huang L; Zhou J; Duan Y; Zhang Z; Wang X; Huang P; Tan S; Hu P; Wang J; Huang M Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1958-1968. PubMed ID: 28812134 [TBL] [Abstract][Full Text] [Related]
23. Molecular Imaging of PD-L1 Expression and Dynamics with the Adnectin-Based PET Tracer Stutvoet TS; van der Veen EL; Kol A; Antunes IF; de Vries EFJ; Hospers GAP; de Vries EGE; de Jong S; Lub-de Hooge MN J Nucl Med; 2020 Dec; 61(12):1839-1844. PubMed ID: 32358092 [No Abstract] [Full Text] [Related]
25. Monitoring early responses to irradiation with dual-tracer micro-PET in dual-tumor bearing mice. Wang H; Liu B; Tian JH; Xu BX; Guan ZW; Qu BL; Liu CB; Wang RM; Chen YM; Zhang JM World J Gastroenterol; 2010 Nov; 16(43):5416-23. PubMed ID: 21086558 [TBL] [Abstract][Full Text] [Related]
26. Characterization of an Orthotopic Colorectal Cancer Mouse Model and Its Feasibility for Accurate Quantification in Positron Emission Tomography. Rapic S; Vangestel C; Verhaeghe J; Van den Wyngaert T; Hinz R; Verhoye M; Pauwels P; Staelens S; Stroobants S Mol Imaging Biol; 2017 Oct; 19(5):762-771. PubMed ID: 28194632 [TBL] [Abstract][Full Text] [Related]
27. Chemoimmunotherapy by combining oxaliplatin with immune checkpoint blockades reduced tumor burden in colorectal cancer animal model. Wang W; Wu L; Zhang J; Wu H; Han E; Guo Q Biochem Biophys Res Commun; 2017 May; 487(1):1-7. PubMed ID: 28042031 [TBL] [Abstract][Full Text] [Related]
28. Screening of radiotracer for diagnosis of colorectal cancer liver metastasis based on MACC1-SPON2. Jiang H; Guo W; Huang K; Jiang H; Zhang R; Hu H; Lin X; Wang S Abdom Radiol (NY); 2021 Jul; 46(7):3227-3237. PubMed ID: 33712897 [TBL] [Abstract][Full Text] [Related]
29. In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1. Rubins DJ; Meng X; McQuade P; Klimas M; Getty K; Lin SA; Connolly BM; O'Malley SS; Haley H; Purcell M; Gantert L; Holahan M; Lindgren J; Eklund P; Ekblad C; Frejd FY; Hostetler ED; González Trotter DE; Evelhoch JL Mol Imaging Biol; 2021 Apr; 23(2):241-249. PubMed ID: 33098025 [TBL] [Abstract][Full Text] [Related]
30. Fang J; Zhang J; Meng L; Li H; Xia D; Wang Y; Chen H; Liao Z; Zhuang R; Li Y; Zhang X; Guo Z Mol Pharm; 2024 Apr; 21(4):1942-1951. PubMed ID: 38447198 [TBL] [Abstract][Full Text] [Related]
31. Automated Synthesis and Preclinical Evaluation of Optimized Integrin α6-Targeted Positron Emission Tomography Imaging of Pancreatic Cancer. Chen L; Fu H; He H; Lou K; Li Q; Ye J; Feng G; Yu C Mol Pharm; 2023 Aug; 20(8):4277-4284. PubMed ID: 37463487 [TBL] [Abstract][Full Text] [Related]
32. Identification of a CEACAM5 targeted nanobody for positron emission tomography imaging and near-infrared fluorescence imaging of colorectal cancer. Xiao Y; Mei C; Xu D; Yang F; Yang M; Bi L; Mao J; Pang P; Li D Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2305-2318. PubMed ID: 36914753 [TBL] [Abstract][Full Text] [Related]
33. Preclinical Kinetic Analysis of the Caspase-3/7 PET Tracer 18F-C-SNAT: Quantifying the Changes in Blood Flow and Tumor Retention After Chemotherapy. Palner M; Shen B; Jeon J; Lin J; Chin FT; Rao J J Nucl Med; 2015 Sep; 56(9):1415-21. PubMed ID: 26045308 [TBL] [Abstract][Full Text] [Related]
35. Enhancing anti-tumor immunity through liposomal oxaliplatin and localized immunotherapy via STING activation. Gu Z; Hao Y; Schomann T; Ossendorp F; Ten Dijke P; Cruz LJ J Control Release; 2023 May; 357():531-544. PubMed ID: 37030544 [TBL] [Abstract][Full Text] [Related]
36. STING signaling is a potential immunotherapeutic target in colorectal cancer. Chon HJ; Kim H; Noh JH; Yang H; Lee WS; Kong SJ; Lee SJ; Lee YS; Kim WR; Kim JH; Kim G; Kim C J Cancer; 2019; 10(20):4932-4938. PubMed ID: 31598165 [No Abstract] [Full Text] [Related]
37. ImmunoPET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer with a Dual-Labeled Bispecific Antibody Fragment. Luo H; England CG; Goel S; Graves SA; Ai F; Liu B; Theuer CP; Wong HC; Nickles RJ; Cai W Mol Pharm; 2017 May; 14(5):1646-1655. PubMed ID: 28292180 [TBL] [Abstract][Full Text] [Related]
38. Baseline [(18)F]FMISO μPET as a Predictive Biomarker for Response to HIF-1α Inhibition Combined with 5-FU Chemotherapy in a Human Colorectal Cancer Xenograft Model. De Bruycker S; Vangestel C; Van den Wyngaert T; Wyffels L; Wouters A; Pauwels P; Staelens S; Stroobants S Mol Imaging Biol; 2016 Aug; 18(4):606-16. PubMed ID: 26728163 [TBL] [Abstract][Full Text] [Related]
39. A novel Guan SS; Wu CT; Liao TZ; Lin KL; Peng CL; Shih YH; Weng MF; Chen CT; Yeh CH; Wang YC; Liu SH Eur J Pharm Biopharm; 2021 Nov; 168():38-52. PubMed ID: 34450241 [TBL] [Abstract][Full Text] [Related]
40. Synergistic antitumor effect of brusatol combined with cisplatin on colorectal cancer cells. Chen HM; Lai ZQ; Liao HJ; Xie JH; Xian YF; Chen YL; Ip SP; Lin ZX; Su ZR Int J Mol Med; 2018 Mar; 41(3):1447-1454. PubMed ID: 29328398 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]